Yu Kataoka, Satoshi Kitahara, Sayaka Funabashi, Hisashi Makino, Masaki Matsubara, Miki Matsuo, Yoko Omura-Ohata, Ryo Koezuka, Mayu Tochiya, Tamiko Tamanaha, Tsutomu Tomita, Kyoko Honda-Kohmo, Michio Noguchi, Kota Murai, Kenichiro Sawada, Takamasa Iwai, Hideo Matama, Satoshi Honda, Masashi Fujino, Kazuhiro Nakao, Shuichi Yoneda, Kensuke Takagi, Fumiyuki Otsuka, Yasuhide Asaumi, Kiminori Hosoda, Stephen J Nicholls, Satoshi Yasuda, Teruo Noguchi
BACKGROUND AND AIMS: Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet. METHODS: The OPTIMAL study was a prospective randomized controlled study to compare the efficacy of 48-week continuous glucose monitoring- and HbA1c-guided glycemic control on near infrared spectroscopty (NIRS)/intravascular ultrasound (IVUS)-derived plaque measures in 94 statin-treated patients with T2D (jRCT1052180152, UMIN000036721)...
June 2024: Atheroscler Plus